Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gerilimzumab + Methotrexate in Rheumatoid Arthritis
NCT04179513Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Aug 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of gerilimzumab in rheumatoid arthritis (RA) (2 arms), sponsored by Genor Biopharma. Primary endpoints: Adverse Effect, AE up to 224 days, Serious Adverse Effect up to 224 days and 4 more. Status: unknown.
02
Drugs
gerilimzumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04179513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179513.